AUROBINDO

PRESS RELEASE

10th June 2011

Aurobindo Pharma receives final approval for Ramipril Capsules

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Ramipril Capsules USP 1.25mg, 2.5mg, 5mg and 10mg

Ramipril Capsules USP 1.25mg, 2.5mg, 5mg and 10mg is the generic equivalent to the reference listed drug Altace® Capsules 1.25mg, 2.5mg, 5mg and 10mg of King Pharmaceuticals Inc. Ramipril Capsules are indicated for the treatment of hypertension and falls under the Cardiovascular (CVS) therapeutic segment. The product has a market size of approximately USD 95 million for the twelve months ending September 2010 according to IMS and will be launched soon.

Aurobindo now has a total of 138 ANDA approvals (108 Final approvals and 30 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com